| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11010521 | Journal of Stroke and Cerebrovascular Diseases | 2018 | 7 Pages |
Abstract
Cilostazol is associated with a decreased risk of symptomatic vasospasm and may be clinically useful in the treatment of delayed cerebral vasospasm in patients with aSAH. Our results highlight the need for a large multi-center trial to confirm the observed association.
Related Topics
Health Sciences
Medicine and Dentistry
Clinical Neurology
Authors
Hamidreza MD, MPH, Aaron MD, Mohan MD, Wazim MD, Navid MD, Muhammed MD,